Publications by authors named "Craig A Vargo"
Background: Additional use of cyclin-dependent kinase 4/6 inhibitors with endocrine therapy improves progression-free survival (PFS) in advanced hormone receptor (HR)-positive HER2-negative breast cancer. However, neutropenia is a common reason for dose reductions, leading to concerns about palbociclib efficacy at lower doses. A safety analysis confirmed no PFS differences between palbociclib doses in the second-line setting, but to our knowledge, this has not been evaluated for first-line treatment.
View Article and Find Full Text PDFBackground: Pertuzumab-based neoadjuvant chemotherapy (NAC) has demonstrated successful pathologic complete response (pCR) rates when administered to patients with human epidermal growth factor receptor 2 (HER2)-positive, locally advanced breast cancer and has become standard of care. This study aimed to identify pCR rates in patients receiving a variety of pertuzumab-based NAC regimens. The effect of the addition of an anthracycline and impact of anthracycline and taxane sequencing on pCR was also assessed.
View Article and Find Full Text PDFArticle Synopsis
- The study focuses on managing treatment resistance in advanced breast cancer using palbociclib and letrozole in postmenopausal women who have already undergone multiple lines of endocrine therapy.
- Researchers analyzed data from 53 patients and found that the median time to treatment failure with this combination was 6.3 months, and the progression-free survival was about 6.4 months.
- The findings suggest that palbociclib and letrozole can be effective as a second-line treatment for metastatic breast cancer, demonstrating notable benefits with manageable toxicity levels.
Article Synopsis
- * Out of 46 patients, 45.6% experienced dose reductions or interruptions during the first treatment cycle, primarily due to adverse effects like stomatitis, fatigue, and diarrhea.
- * The findings highlight the importance of patient education and close monitoring in the initial month of therapy, given the median progression-free survival was only 6.2 months.
Study Objective: To evaluate real-world clinical and economic outcomes in patients with Clostridium difficile infection (CDI) treated with fidaxomicin.
Design: Retrospective case series.
Setting: Academic medical center.
Study Objectives: To determine the frequency of sinusoidal obstructive syndrome (SOS) in patients undergoing allogeneic hematopoietic cell transplantation who received graft-versus-host disease (GVHD) prophylaxis with sirolimus and tacrolimus, and to assess whether the occurrence of SOS correlates with immunosuppressant levels.
Design: Retrospective cohort study.
Setting: Hematopoietic cell transplant unit at an academic medical center.
Angiogenesis is crucial for development and metastasis of tumors, and vascular endothelial growth factor (VEGF) is a key mediator of this process. The importance of VEGF in tumorigenesis and tumor progression makes it an attractive target for the development of anticancer therapies. Inhibition of angiogenesis has shown promising clinical efficacy; however, not all patients treated with antiangiogenic agents derive benefit from them.
View Article and Find Full Text PDF